# US 2014/0271474 A1 · Inhibitor probes for imaging sodium-glucose cotransporters in health and disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0271474 A1
- Document ID: US20140271474A1
- Status: Published application
- Kind: A1
- Application number: 14/126,395
- Filed: 2012-06-14
- Published: 2014-09-18
- Earliest claimed: 2011-06-14
- Assignees: The Regents of the University of California
- Inventors: Ernest M. Wright; Jorge R. Barrio
- Web page: https://patentgrep.com/patent/US20140271474A1

## CPC

- C07H 19/01: sharing oxygen
- A61K 51/0491: {Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07H 15/207: Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
- C07H 15/26: Acyclic or carbocyclic radicals, substituted by hetero rings
- C07H 17/02: Heterocyclic radicals containing only nitrogen as ring hetero atoms
- G01N 33/5091: {for testing the pathological state of an organism}
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Radiolabeled tracers for binding to sodium/glucose cotransporters (SGLTs), and their synthesis, are provided. The tracers are high-affinity inhibitors of SGLTs, glycosides labeled with radioactive halogens. Also provided are in vivo and in vitro techniques for using the tracers as analytical tools to study the biodistribution and regulation of SGLTs in health and disease, and to evaluate therapeutic interventions. The ability to monitor radiolabel tracer disposition in real time enables the design of new SGLT inhibitors with lower metabolism and higher efficiency.

## Claims

### Claim 1

A radiolabeled sodium/glucose cotransporter inhibitor comprising a six membered sugar ring connected to a Ring A which is in turn connected to a Ring B wherein the inhibitor is a compound of the formula:
Where X═—O—, —S—, —C—, CH2, C—(H)alkyl, C(alkyl)2), —NH— or N-alkyl,
1A, 1B, 2A, 2B, 3A and 3B═—H, —OH, —O—, alkyl, —F, —18F, —I, —123I, —124I or Z connected to the Ring A and Ring B moiety)
4A and 4B═—H, —OH, —F, 18F, —I, —123I, —124I, or Z connected to the Ring A and Ring B moiety, and
5A and 5B═—H, —OH, —CH2OH, —F, 18F, —I, 123I, —124I—CH2, —CH218F, —CH2I, CH2123I, CH2124I, Z or CH2Z, where Z is connected to the Ring A and Ring B moiety, and D- and L- isomers thereof,
Where Ring A and Ring B are selected from:
Phenyl rings,
Heterocyclic rings which can be a pyrrole, imidazole, thioimidazole, pyridine, furane, oxazole, pyrimidine or pyrolidine rings, or
Fused aromatic rings which can be a naphthalene, benzothiazole, benzopyrazole, quinoline, benzoxazole or indole rings,
Where the R substitutions in Ring A and Ring B are one or more halogens selected from the group consisting of F, Br, I or 18F, 123I, 124I, 75Br or an alkyl, alkoxy, alkylamine, alkylthio, aryl, or a heterocyclic ring,
Where the Y link is —CH2, alkyl substituted CH2, —NH, N-alkyl, —O—, —S—, or
Where the Z link comprises either
Ring A attached directly to C1, C2, C3, C4, C5 or C5CH2— in the six member sugar ring ,
or
Ring A attached to C1, C2, C3, C4, C5, C5CH2— via Z where is Z is CH2, or an alkyl substituted CH2, —NH, N-alkyl, —O—, or —S—.

### Claim 2 (depends on 1)

A method of in vivo assessment of sodium/glucose cotransporter (SGLT) distribution or activity in a mammal, wherein said mammal is selected from the group consisting of humans, non-human primates, rodents, wild-type rodents, transgenic rodents and knockout rodents, comprising administering to said mammal one or more compounds set forth in claim 1.

### Claim 3 (depends on 2)

The method of claim 2 wherein said mammal includes non-human and human subjects with disturbances in glucose homeostasis.

### Claim 4 (depends on 3)

The method of claim 3 wherein said disturbances in glucose homeostasis includes Type 1 and Type 2 diabetes, cancer, heart disease, gout, and brain disorders.

### Claim 5 (depends on 2)

The method of claim 2, wherein the assessment comprises the use of radiographic techniques.

### Claim 6 (depends on 5)

The method of claim 5 wherein the radiographic techniques comprises positron emission tomography (PET), micro-PET, mini-PET, or single-photon emission computerized tomography (SPECT)or radioautoradiography.

### Claim 7 (depends on 1, 2)

The method of claim 2 wherein one or more of the compounds set forth in claim 1 are administered to the mammal by oral delivery or injection, along with at least one agent selected from the group consisting of sodium ion, phlorizin, glucose, galactose, SGLT inhibitors and a drug.

### Claim 8 (depends on 7)

The method of claim 7 wherein the drug is insulin.

### Claim 9 (depends on 1)

A method of detecting a sodium/glucose cotransporter (SGLT) in vitro, comprising:
forming a compound as set forth in claim 1, exposing one or more single mammalian cells, a mammalian tissue sample or a mixtures thereof to said compound to form radiolabeled cells or tissue, and assessing the radioactivity of said radiolabeled cells or tissue.

### Claim 10

A method of monitoring sodium/glucose cotransporter activity in a mammal, in vivo, comprising: administering to a mammal a bolus of a tracer for SGLT activity, and a compound which is an inhibitor for sodium/glucose cotransporter 2 (SGLT2), but not an inhibitor of sodium/glucose cotransporter 1 (SGLT1); generating radiographic data indicative of tracer uptake in the mammal by scanning the mammal using a radiographic technique; and, using the radiographic data to assess the distribution of SGLT1 and SLGT2 in the mammal, the radiographic technique comprising one or more computerized methods.

### Claim 11 (depends on 1)

A method of preparing the compounds of claim 1 comprising reacting a sugar with an aryl compound in accordance with the procedure set forth in FIG. 7.

### Claim 12

Synthesis of radiolabeled, [18F]- dapagliflozin ((1S)-1,5-anhydro-1-C-{4-chloro-3[(4-ethoxyphenyl)methyl]phenyl}-[18F]-4-deoxy-D-glucitol) comprising the procedure as set forth in FIG. 4.

### Claim 13 (depends on 1)

A sodium/glucose cotransporter 2 inhibitor for use in the treatment of diabetes and other related disorders and a radiolabeled sodium/glucose cotransporter 2 inhibitor for imaging as set forth in claim 1 comprising 3-O-alkyl or 3 deoxy-D-glucose derivatives, said derivatives having a low in vivo metabolism and low rate of glucuronidation.
